Image credit: Canva
Neuroendocrine neoplasms are rare cancers in the gastrointestinal tract, pancreas, lungs, adrenal glands and other parts of the body. Many of these cancers have a high risk of relapse and a low chance of survival. A trial led by Jaydira Del Rivero, M.D., Associate Research Physician in the Developmental Therapeutics Branch, is studying a new drug for these cancers.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Kimberley J. Cooper at (240) 858-7989 or kimberley.cooper@nih.gov
Clinicaltrials.gov identifier: NCT06041516
NCI Protocol ID: IRB001547
Official Title: A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow, treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
